Previous close | 41.62 |
Open | 42.33 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 42.30 - 44.76 |
52-week range | 25.60 - 77.60 |
Volume | |
Avg. volume | 420,480 |
Market cap | 1.098B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.31 |
Earnings date | 09 Aug 2024 - 13 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 64.33 |
Riot Platforms increased its stake in bitcoin-mining firm Bitfarms Technologies. Corvex Management bought more shares of uniform and workplace-supplies firm Vestis.
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an underwritten offering of 4,944,000 shares of its common stock at a price of $36.00 per share. The aggregate gross proceeds to Disc from this offering are expected to be approximately $178.0
Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path forwardAdditional data from the ongoing Phase 1b trial of DISC-0974 in myelofibrosis (MF) patients continued to demonstrate greater than 60% hematologic response rates, with durable increases in hemoglobin levels and reductions in transfusion burdenPositive data from initial single-ascending dose (